List of Excipients in Branded Drug CARBOCAINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hospira Inc	CARBOCAINE	mepivacaine hydrochloride	0409-1036	CALCIUM CHLORIDE
Hospira Inc	CARBOCAINE	mepivacaine hydrochloride	0409-1036	HYDROCHLORIC ACID
Hospira Inc	CARBOCAINE	mepivacaine hydrochloride	0409-1036	POTASSIUM CHLORIDE
Hospira Inc	CARBOCAINE	mepivacaine hydrochloride	0409-1036	SODIUM CHLORIDE
Hospira Inc	CARBOCAINE	mepivacaine hydrochloride	0409-1036	SODIUM HYDROXIDE
Hospira Inc	CARBOCAINE	mepivacaine hydrochloride	0409-1036	WATER

Generic Drugs Containing CARBOCAINE

Company	Ingredient	NDC	Excipient
Septodont Inc	mepivacaine hydrochloride	0362-0753	HYDROCHLORIC ACID
Septodont Inc	mepivacaine hydrochloride	0362-0753	SODIUM CHLORIDE
Septodont Inc	mepivacaine hydrochloride	0362-0753	SODIUM HYDROXIDE
Septodont Inc	mepivacaine hydrochloride	0362-0753	WATER
Caresteam Health Inc	mepivacaine hydrochloride	31382-753	SODIUM CHLORIDE
Caresteam Health Inc	mepivacaine hydrochloride	31382-753	WATER

What are the Most Frequently-Used Excipients in CARBOCAINE?

# Of NDCs	Excipient
1	HYDROCHLORIC ACID
2	SODIUM CHLORIDE
1	SODIUM HYDROXIDE
2	WATER

CARBOCAINE Excipient Strategy and Commercial Opportunities for Mepivacaine Injection

Last updated: September 24, 2026

CARBOCAINE is a mepivacaine hydrochloride local anesthetic used primarily in dental anesthesia, infiltration, nerve block, epidural, and other regional anesthesia procedures. Its excipient strategy is commercially attractive because the active ingredient is mature, generic competition is established, and differentiation depends on presentation, preservative status, vasoconstrictor compatibility, container closure, and workflow efficiency rather than on a new chemical entity.

The strongest opportunities are preservative-free multidose alternatives, dental cartridges, ready-to-administer formats, low-particulate packaging, improved stability, and differentiated combinations with vasoconstrictors. Excipient-only patent protection is likely to be weak. Commercial protection should instead combine formulation claims with container systems, manufacturing controls, device claims, and clinical-use positioning.

What is CARBOCAINE and which excipients are used?

CARBOCAINE is the brand name for mepivacaine hydrochloride injection. Mepivacaine is an amide-type local anesthetic that blocks sodium channels and produces regional loss of sensation. Unlike lidocaine, mepivacaine has limited intrinsic vasodilatory activity, which allows some formulations to be used without a vasoconstrictor.

US labeling identifies several concentrations and presentations, including 1%, 1.5%, and 2% mepivacaine hydrochloride injections, as well as formulations containing levonordefrin. Depending on the presentation, excipients may include sodium chloride, water for injection, pH-adjusting agents, and antimicrobial preservatives such as methylparaben. Excipients vary by vial, cartridge, preservative-free presentation, concentration, and manufacturer. The applicable product label controls the formulation for each commercial SKU (DailyMed, n.d.-a).

Formulation element	Strategic function	Commercial relevance
Sodium chloride	Tonicity adjustment	Supports isotonicity and injection comfort
Water for injection	Vehicle	Standard parenteral solvent
Hydrochloric acid or sodium hydroxide	pH adjustment	Controls stability, solubility, and tolerability
Methylparaben, where present	Antimicrobial preservation	Enables multidose packaging but creates preservative-sensitivity concerns
Levonordefrin	Vasoconstrictor active ingredient	Extends anesthesia and reduces systemic absorption in selected applications
Container closure materials	Product protection and dose delivery	Can affect adsorption, extractables, particulate levels, and shelf life

A commercial formulation assessment must distinguish the branded CARBOCAINE product from generic mepivacaine hydrochloride products. The same active ingredient may be supplied with different preservatives, concentrations, container sizes, and labeling.

What formulations are protected by CARBOCAINE excipients?

The original CARBOCAINE formulation is unlikely to provide meaningful current exclusivity based solely on conventional excipients. Mepivacaine is an established active ingredient, and the basic use of sodium chloride, water for injection, pH adjusters, or methylparaben would generally be difficult to protect with broad, enforceable patent claims.

Potentially defensible formulation claims would require a specific technical result, such as:

• A defined pH range that improves long-term stability.
• A low-excipient formulation that reduces injection-site irritation.
• A preservative-free multidose system with validated microbial control.
• A container closure that limits adsorption or leachables.
• A formulation with reduced particulate generation after repeated needle puncture.
• A stable combination of mepivacaine and levonordefrin.
• A cartridge formulation compatible with a specific dental delivery device.
• A formulation that improves stability after temperature excursions.
• A low-volume, high-concentration presentation that reduces procedural waste.

The strongest claims would connect excipient composition to measured performance. A claim covering “mepivacaine with sodium chloride and water” would face substantial prior-art risk. A claim covering a narrow pH, oxygen-control condition, container material, impurity profile, and stability outcome would have greater potential value.

When does CARBOCAINE lose exclusivity?

CARBOCAINE’s active-ingredient exclusivity is effectively historical rather than current. Mepivacaine has been marketed for decades, and generic mepivacaine hydrochloride products are available in the United States and other markets. The commercial issue is therefore not the loss of an imminent basic compound patent. It is the ability to create a differentiated product in a mature generic market.

The relevant exclusivity categories are:

Exclusivity category	CARBOCAINE position
New chemical entity exclusivity	Expired
Basic compound patent protection	Historical and expired for commercial purposes
Original brand formulation protection	Historical; unlikely to block current generic supply
Current FDA regulatory exclusivity	No major current exclusivity is generally associated with the mature product
Product-specific formulation patents	Must be assessed by presentation and applicant
Device or packaging protection	Potentially available for new commercial systems
Trademark protection	Brand-name protection may remain separate from active-ingredient exclusivity

A current Orange Book review should be performed by presentation and applicant because listed patents can change. The commercial entry barrier for a new product is more likely to arise from FDA manufacturing requirements, sterile-fill capability, validated packaging, hospital contracts, and dental distribution than from legacy CARBOCAINE patents (FDA, n.d.-a).

How strong is the CARBOCAINE patent estate?

The patent estate for the legacy product is likely weak as a barrier to standard mepivacaine injection. A new entrant using conventional excipients and standard glass-vial packaging would face limited freedom-to-operate risk from the historical brand formulation.

A new formulation may support stronger protection if it includes several claim layers:

1. Composition claims covering defined excipient concentrations and pH.
2. Stability claims covering degradation limits over a specified period.
3. Container claims covering vial, cartridge, syringe, or polymer components.
4. Manufacturing claims covering oxygen reduction, sterilization, filling, or terminal processing.
5. Device claims covering a dental cartridge or prefilled delivery system.
6. Method-of-use claims tied to a defined patient population or procedure.
7. Trade-secret protection for aseptic processing, filling parameters, or packaging controls.

The patent strategy should avoid reliance on excipient identity alone. Mepivacaine formulations have a predictable technical profile, and routine substitution among common tonicity agents, buffers, preservatives, and container materials may be vulnerable to obviousness arguments.

What excipient strategies create commercial opportunities?

Preservative-free mepivacaine injection

A preservative-free presentation is the most direct opportunity. It can target patients with sensitivity to parabens, institutions that prefer single-dose products, and procedures where preservative exposure is undesirable.

The commercial tradeoff is higher packaging cost and tighter sterility controls. A preservative-free product should use single-dose vials, ampoules, cartridges, or prefilled syringes. A multidose preservative-free product would require robust container-closure integrity and antimicrobial validation, creating a more difficult regulatory and manufacturing program.

Dental cartridges

Dental anesthesia is a natural market for mepivacaine. A cartridge product can differentiate through:

• Low extractables and leachables.
• Reduced breakage.
• Improved plunger glide force.
• Lower residual volume.
• Better compatibility with automated dental injectors.
• Clear labeling of preservative and vasoconstrictor status.
• Improved protection from light and temperature excursions.
• Reduced particulate formation after storage.

The cartridge itself may provide more defensible intellectual property than a conventional excipient combination. Claims can cover the cartridge material, stopper coating, plunger geometry, fill volume, and interaction between the formulation and delivery system.

Mepivacaine with levonordefrin

CARBOCAINE has historically included formulations with levonordefrin. A combination product can support a separate commercial position, but it creates additional stability and regulatory complexity. The manufacturer must control oxidation, pH, color change, impurity formation, and compatibility with container components.

A combination formulation may be differentiated through an oxygen-controlled headspace, antioxidant strategy, light-protective packaging, or a defined degradation profile. Those features may support patent claims if the technical effect is demonstrated.

Ready-to-use syringes

Prefilled syringes can reduce preparation time and medication errors in operating rooms, ambulatory surgery centers, emergency departments, and dental settings. The principal formulation issues are:

• Syringe-material compatibility.
• Silicone oil and particulate control.
• Plunger-force consistency.
• Extractables and leachables.
• Stability during shipping.
• Dose-volume optimization.
• Compatibility with needle-free or standard luer systems.

A prefilled format may command a higher price than a vial, but adoption depends on reimbursement, pharmacy and therapeutics committee approval, and demonstrable workflow savings.

Low-waste presentations

Mepivacaine is frequently administered in small procedural volumes. A presentation that minimizes residual drug can reduce waste and lower the effective cost per procedure. Opportunities include smaller fill volumes, dose-concentrated formulations, calibrated cartridges, and unit-dose packaging matched to common dental or regional-anesthesia doses.

This strategy may produce commercial value without requiring a novel excipient. The differentiation would come from packaging engineering and institutional economics.

What is the FDA regulatory status of CARBOCAINE?

Mepivacaine hydrochloride injection is an established prescription local anesthetic marketed through approved drug applications and abbreviated new drug applications. Generic products must demonstrate pharmaceutical equivalence and bioequivalence where applicable, comply with current good manufacturing practice requirements, and satisfy sterile injectable quality standards.

FDA review will focus on:

• Identity, strength, quality, and purity.
• Sterility and bacterial endotoxin limits.
• Particulate matter.
• Container-closure integrity.
• Extractables and leachables.
• Stability through the proposed shelf life.
• Preservative effectiveness where applicable.
• Compatibility with the labeled delivery system.
• Labeling for single-dose and multidose use.
• Compatibility of combination products with levonordefrin.

An excipient change in an existing approved product may require a supplement, while a materially different presentation may require a new abbreviated application or other regulatory pathway. The classification depends on the proposed product, reference listed drug, formulation differences, and FDA’s determination of pharmaceutical equivalence.

What is the Orange Book status of CARBOCAINE?

The Orange Book is relevant for approved prescription drug products and listed patents, but it is not a complete source for all formulation, device, manufacturing, or international rights. A standard mepivacaine product should be evaluated by:

• Active ingredient and dosage form.
• Applicant and product number.
• Concentration.
• Preservative status.
• Vial or cartridge presentation.
• Listed patents and exclusivity codes.
• Therapeutic equivalence rating.
• Discontinued-product status.

Because generic mepivacaine products have been available for many years, a new entrant should not assume that the CARBOCAINE brand itself creates a blocking patent position. Paragraph IV risk would arise only if a relevant, unexpired Orange Book patent were listed for the reference product or a related product. For a conventional mepivacaine injection, the principal legal exposure is more likely to involve formulation, packaging, or device patents owned by later entrants.

Which companies are challenging CARBOCAINE?

Generic competition is generally directed at mepivacaine hydrochloride rather than at the CARBOCAINE trademark. The competitive field includes branded and generic injectable manufacturers, dental anesthetic suppliers, contract manufacturers, and specialty distributors.

The most relevant competitor groups are:

• Generic sterile-injectable manufacturers.
• Dental cartridge manufacturers.
• Suppliers of lidocaine, prilocaine, articaine, bupivacaine, and ropivacaine.
• Regional-anesthesia product companies.
• Contract development and manufacturing organizations with cartridge or prefilled-syringe capacity.

Competitive risk is highest for standard 1% to 2% injectable products. Differentiation is more feasible in preservative-free, cartridge, combination, and ready-to-use formats.

What generic entry risks exist for a new CARBOCAINE formulation?

A new product faces several entry risks even if no blocking patent is identified.

Manufacturing risk

Sterile injectable manufacturing requires validated aseptic processes, reliable filling lines, container-closure controls, and particulate management. Cartridge and prefilled-syringe formats require specialized equipment and higher component qualification costs.

Regulatory risk

A formulation that differs from the reference product may create questions about equivalence, preservative status, delivery system, or labeling. The development program should establish that excipient differences do not alter safety, performance, or administration.

Supply-chain risk

Glass cartridges, elastomeric closures, plungers, and specialty syringes may have limited qualified suppliers. A single-source component can create a greater commercial barrier than a patent.

Pricing risk

Mepivacaine is a mature molecule. Hospitals and dental distributors may treat it as a commodity unless the new format reduces preparation time, waste, contamination risk, or procurement complexity.

Substitution risk

Clinicians can substitute lidocaine or other local anesthetics depending on onset, duration, toxicity profile, vasoconstrictor use, and procedural requirements. A premium product must show a practical advantage over both generic mepivacaine and competing anesthetics.

How does CARBOCAINE compare with competing local anesthetics?

Product	Active ingredient	Typical differentiation	Excipient opportunity
CARBOCAINE	Mepivacaine	Low vasodilatory effect; dental and regional anesthesia	Preservative-free, cartridge, levonordefrin combination
Lidocaine injection	Lidocaine	Broad use, rapid onset, extensive generic supply	Ready-to-use and buffered formats
Articaine dental injection	Articaine	Dental-specific positioning and rapid onset	Cartridge stability and delivery systems
Bupivacaine injection	Bupivacaine	Longer duration	Low-concentration and liposomal delivery systems
Ropivacaine injection	Ropivacaine	Long-duration regional anesthesia	Preservative-free and ready-to-administer formats
Prilocaine injection	Prilocaine	Dental and local-anesthesia use	Combination and cartridge products

Mepivacaine’s best commercial position is in applications where clinicians value reliable anesthesia without the same level of vasodilation associated with some alternatives. Its weakest position is the undifferentiated standard vial, where price and supply reliability dominate.

What licensing deals could support CARBOCAINE commercialization?

Licensing opportunities are more likely to involve technology and distribution than the legacy CARBOCAINE brand. Relevant deal structures include:

• Licensing a dental cartridge platform.
• Acquiring rights to a preservative-free injectable technology.
• Partnering with a sterile injectable CDMO.
• Licensing a prefilled syringe or autoinjector-compatible container system.
• Regional distribution agreements with dental suppliers.
• Co-development with a hospital injectable company.
• Acquiring formulation patents covering stability or packaging.
• Contract manufacturing with an option for territorial exclusivity.

A commercial agreement should allocate responsibility for FDA supplements, product complaints, pharmacovigilance, recalls, component qualification, and supply interruptions. Territorial rights are particularly important because mepivacaine formulations and brand ownership differ across jurisdictions.

What geographic markets offer the best opportunity?

The United States offers a large and regulated injectable market but has significant price pressure and buyer concentration. Dental channels can support differentiated cartridges, while hospitals may favor standard vials unless a new format reduces labor or contamination risk.

Europe requires country-specific commercial and regulatory planning. Mepivacaine is used in dental and regional anesthesia markets, but product names, pack sizes, preservatives, and reimbursement structures vary.

Emerging markets may offer volume growth but place greater emphasis on price, local registration, supply reliability, and room-temperature stability. A formulation with less demanding storage requirements could have commercial value if supported by real-time stability data.

The most defensible geographic strategy is often:

1. Launch a differentiated presentation in the United States.
2. Expand through dental and hospital distributors.
3. Use the same qualified formulation and container platform in Europe.
4. Adapt pack sizes and labeling for price-sensitive markets.
5. Protect manufacturing know-how and supply contracts across regions.

How should revenue exposure be modeled?

Revenue should be modeled by presentation rather than by active ingredient alone.

Revenue driver	Standard vial	Dental cartridge	Prefilled syringe
Unit price	Low	Moderate	High
Manufacturing complexity	Low to moderate	Moderate to high	High
Switching cost	Low	Moderate	Moderate
Hospital demand	Established	Limited by setting	Increasing where workflow matters
Patent potential	Low	Moderate	Moderate to high
Margin opportunity	Limited	Better	Highest if adoption occurs
Main risk	Commodity pricing	Component supply	Regulatory and device complexity

The commercial case is strongest where a formulation or presentation can command a premium while reducing preparation time, waste, contamination risk, or inventory complexity. A conventional mepivacaine vial is unlikely to support substantial premium pricing without supply, quality, or service differentiation.

Key Takeaways

• CARBOCAINE is a mature mepivacaine hydrochloride product with extensive generic competition.
• Standard excipients such as sodium chloride, water for injection, pH adjusters, and methylparaben are unlikely to provide strong standalone patent protection.
• The highest-value opportunities are preservative-free products, dental cartridges, prefilled syringes, low-waste formats, and stable mepivacaine-levonordefrin combinations.
• Device, container, manufacturing, and stability claims are more defensible than broad excipient-composition claims.
• Current exclusivity risk is likely to be limited for standard mepivacaine injection, but product-specific Orange Book and patent reviews remain necessary for any launch decision.
• FDA and commercial barriers are concentrated in sterile manufacturing, container qualification, particulate control, supply reliability, and buyer adoption.
• The standard vial is a low-margin commodity. Differentiated delivery systems offer the stronger commercial pathway.

FAQs

Is CARBOCAINE the same as mepivacaine?

Yes. CARBOCAINE is a brand associated with mepivacaine hydrochloride injection. Generic products may use different excipients, container systems, concentrations, and preservative status.

Does CARBOCAINE contain preservatives?

Some presentations may contain an antimicrobial preservative such as methylparaben, while other presentations are preservative-free. The specific product label and package insert control.

Can a preservative-free mepivacaine product receive patent protection?

Yes, but preservative-free status alone is usually weak patent subject matter. Stronger protection may arise from a defined formulation, container system, microbial-control method, stability profile, or prefilled delivery device.

Is levonordefrin an excipient in CARBOCAINE?

No. Levonordefrin is an active vasoconstrictor ingredient when included. It creates a combination drug product rather than a conventional excipient-only formulation.

What is the most attractive commercial format for a new mepivacaine product?

Dental cartridges and ready-to-administer syringes generally offer more differentiation than standard vials. Their success depends on component supply, workflow benefits, regulatory clearance, and the ability to command a premium in a price-sensitive market.

References

1. DailyMed. (n.d.-a). CARBOCAINE- mepivacaine hydrochloride injection, solution. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

3. U.S. Food and Drug Administration. (n.d.-b). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

4. United States Pharmacopeia. (2024). General chapter <797>: Pharmaceutical compounding—Sterile preparations. United States Pharmacopeial Convention.

5. U.S. Food and Drug Administration. (2016). Container closure systems for packaging human drugs and biologics: Chemistry, manufacturing, and controls documentation. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/container-closure-systems-packaging-human-drugs-and-biologics.